Genetic studies suggest that genes of myeloid origin such as TREM2 and CD33 are implicated in AD, linking the innate immune component to the pathophysiology and therapeutic direction of this disorder (Harold et al., 2009; Lambert et al., 2009; Seshadri et al., 2010; Hollingworth et al., 2011; Naj et al., 2011; Guerreiro et al., 2013; Jin et al., 2014). The gene discussed is CD33; the disease is Alzheimer disease.